LIGELIZUMAB REDUCES RESCUE MEDICATION USE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS

被引：3
|
作者：
Sitz, K.
Soong, W.
Lanier, B.
Kobayashi, K.
Barve, A.
Hua, E.
Janocha, R.
Severin, T.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2019年 / 123卷 / 05期
关键词：
D O I：
10.1016/j.anai.2019.08.257
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P153
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [1] Remibrutinib (LOU064) reduces the use of rescue medication in patients with chronic spontaneous urticaria: Findings from a Phase 2b study
    Maurer, M.
    Reed, J.
    Staubach-renz, P.
    Lheritier, K.
    Walsh, P.
    Meti, V.
    Nikolaev, I.
    Haemmerle, S.
    Gimenez-Arnau, A. M.
    ALLERGY, 2023, 78 : 14 - 14
  • [2] Remibrutinib monotherapy reduced rescue medication in chronic spontaneous urticaria patients: Findings from a Phase 2b extension study
    Clore, Lee
    Carr, Warner
    Tillinghast, Jeffrey
    Jain, Vipul
    Reed, John
    Staubach, Petra
    Lheritier, Karine
    Walsh, Pauline
    Nikolaev, Ivan
    Haemmerle, Sibylle
    Gimenez-Arnau, Ana Maria
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB6 - AB6
  • [3] Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis
    Staubach, Petra
    Alvaro-Lozano, Montserrat
    Sekerel, Bulent Enis
    Maurer, Marcus
    Ben-Shoshan, Moshe
    Porter, Miriam
    Hua, Eva
    Ji, Yan
    Burciu, Alis
    Savelieva, Marina
    Severin, Thomas
    Drollmann, Anton
    Bienczak, Andrzej
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2023, 34 (07)
  • [4] High rate of complete response achieved with ligelizumab in patients with moderate to severe chronic spontaneous urticaria throughout the phase 2b core study
    Bernstein, Jonathan A.
    Maurer, Marcus
    Gimenez-Arnau, Ana
    Soong, Weily
    Sitz, Karl
    Hua, Eva
    Barbier, Nathalie
    Barve, Avantika
    Severin, Thomas
    Janocha, Reinhold
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB137 - AB137
  • [5] Remibrutinib Treatment Improves Itch and Sleep in Chronic Spontaneous Urticaria Patients: Phase 2b Study Results
    Hsu, Connie
    Snyder, Robert
    Clore, Lee
    Jain, Vipul
    Gimenez-Arnau, Ana
    Lheritier, Karine
    Walsh, Pauline
    Haemmerle, Sibylle
    Wells, Michael
    Nikolaev, Ivan
    Maurer, Marcus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB82 - AB82
  • [6] REMIBRUTINIB TREATMENT IMPROVES SLEEP AND ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS: PHASE 2B STUDY RESULTS
    Clore, L.
    Jain, V.
    Gimenez-Arnau, A.
    Lheritier, K.
    Walsh, P.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S32 - S32
  • [7] REMIBRUTINIB TREATMENT IMPROVES HIVE SEVERITY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
    Sitz, K.
    Gimenez-Arnau, A.
    Hayama, K.
    Jain, V.
    Lheritier, K.
    Walsh, P.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S11 - S11
  • [8] REMIBRUTINIB IMPROVES CHRONIC SPONTANEOUS URTICARIA IN PATIENTS IRRESPECTIVE OF CU-INDEX: RESULTS FROM PHASE 2B STUDY
    Carr, W.
    Sitz, K.
    Jain, V.
    Gimenez-Arnau, A.
    Lheritier, K.
    Nikolaev, L.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S11 - S11
  • [9] REMIBRUTINIB SHOWED GOOD STABILITY OF RESPONSE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY
    Tillinghast, J.
    Jain, V.
    Maurer, M.
    Gimenez-Arnau, A.
    Reich, A.
    Ortmann, C.
    Walsh, P.
    Haemmerle, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S41 - S41
  • [10] Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study
    Ben-Shoshan, Moshe
    Sekerel, Bulent Enis
    Staubach-Renz, Petra
    Alvaro-Lozano, Montserrat
    Maurer, Marcus
    Drollmann, Anton
    Bienczak, Andrzej
    Porter, Miriam
    Liu, Tian
    Burciu, Alis
    Severin, Thomas
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB179 - AB179
12345